Overview

A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, 200, 300 and 400 mg) of Extended-release Tramadol HCl With Placebo for the Treatment of Osteoarthritis(OA) of the Knee and/or Hip

Status:
Completed

Trial end date:
2003-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the effectiveness of multiple doses of once daily tramadol HCl ER (100, 200, 300 and 400 mg) to placebo in patients with moderate to severe pain due to OA. The study hypothesis is that tramadol HCl ER is safe and effective in the treatment of patients with moderate to severe pain due to OA.

Phase:

Phase 3

Details

Lead Sponsor:

Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.

Treatments:

Tramadol